CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
615.14MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.0980xvs all stocks
52-Week Change
48.72%vs all stocks
Market Capitalization
615.14MUSDvs all stocks (USD)
Enterprise Value
382.87MUSDvs all stocks (USD)
Forward P/E
-6.97xvs Biotechnology peers
Price to Book (MRQ)
2.66xvs Biotechnology peers
Enterprise to EBITDA
-4.17xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-20.72%vs Biotechnology peers
Return on Equity (TTM)
-31.42%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-91.72MUSDvs all stocks (USD)
Net Income (TTM)
-83.49MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-65.41MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-44.70MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-84.04MUSDvs all stocks (USD)
Pre-tax Income
-72.92MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.23MUSDFY2025 · Dec 31, 2025Net Income
-74.15MUSDFY2025 · Dec 31, 2025EBIT
-72.86MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-71.48MUSDFY2025 · Dec 31, 2025Research & Development
63.49MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
20.55MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
11.30MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
63.00KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-74.15MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-62.32MUSDFY2025 · Dec 31, 2025Free Cash Flow
-62.46MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
254.87MUSDFY2025 · Dec 31, 2025Interest Paid
63.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-74.15MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.38MUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.50MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.12MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
116.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.28MUSDFY2025 · Dec 31, 2025Capital Expenditures
-138.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-138.00KUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-489.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-485.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
172.12MUSDFY2025 · Dec 31, 2025Shares Outstanding
18.83MSharesUpdated Jul 19, 2026Float Shares
11.23MSharesUpdated Jul 19, 2026Shares Short
2.14MSharesUpdated Jul 19, 2026Short Ratio
15.21daysvs all stocks
Short % of Shares Outstanding
23.77%vs all stocks
% Held by Insiders
39.34%vs all stocks
% Held by Institutions
74.11%vs all stocks
Total Cash (MRQ)
236.89MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
12.55USDUpdated Jul 19, 2026Total Debt (MRQ)
4.63MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0201xvs Biotechnology peers
Current Ratio (MRQ)
18.51xvs Biotechnology peers
Book Value per Share (MRQ)
12.24USDUpdated Jul 19, 2026Total Assets
261.04MUSDvs all stocks (USD)
Total Current Assets
257.36MUSDFY2025 · Dec 31, 2025Total Liabilities
9.71MUSDFY2025 · Dec 31, 2025Total Non-current Assets
3.68MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
43.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.67MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
253.80MUSDFY2025 · Dec 31, 2025Accounts Payable
1.09MUSDFY2025 · Dec 31, 2025Short-term Debt
1.23MUSDFY2025 · Dec 31, 2025Long-term Debt
43.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-222.74MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
251.33MUSDvs all stocks (USD)
52-Week Low
14.39USDUpdated Jul 19, 202652-Week High
39.53USDUpdated Jul 19, 202652-Week Change
48.72%vs all stocks
Beta
0.0980xvs all stocks
50-Day MA
30.57USDUpdated Jul 19, 2026200-Day MA
24.62USDUpdated Jul 19, 2026Avg 10-Day Volume
230.35KSharesUpdated Jul 19, 2026Avg 30-Day Volume
182.84KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-4.46USDUpdated Jul 19, 2026Other Income / Expense
-119.00KUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.53
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Hainan Shuangcheng Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinhe Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Allogene Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Scitop Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
TTY Biopharm Company Limited
Tier 1ProductionApproval-Gated PipelineRule
Kexing Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Achieve Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou AGS Medtech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Clarity Pharmaceuticals Ltd
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Seers Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Fulcrum Therapeutics Inc.
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Gipta Ofis Kırtasiye ve Promosyon Sanayi Ticaret A.Ş.
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Promotora y Operadora de Infraestructura, S.A.B. de C.V.
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity